TrialTargeted oncology2015

Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial.

Brian I Rini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.